Abstract: M184V and/or T215Y mutations were demonstrated in two of these last five patients.
Development and significance of the HIV-1 reverse transcriptase M184V mutation during combination therapy with lamivudine, zidovudine, and protease inhibitors.
PMID: 10421243
1999
Journal of acquired immune deficiency syndromes (1999)
Abstract: Among ZDV-resistant study subjects at week 24 (n = 17), those with mutant RT M184V codon had a more favorable HIV-1 RNA slope than those with wild-type RT 184M codon (p = .0551).
Abstract: Emergence of the M184V RT mutation at week 48 was detected in 3 of 16 (18.7%) initially drug-naive subjects as opposed to 21 of 40 (52.5%) ZDV-pretreated patients.
Abstract: Multivariate logistic analysis detected HIV-1 RNA load at week 24 as the best predictor of subsequent selection of the M184V mutant (p = .0121).
Abstract: These findings suggest that development of the 3TC-resistance M184V mutation under triple therapy with 3TC, ZDV, and a PI may have unexpected beneficial effects in vi
Presence of mutation conferring resistance to lamivudine in plasma and cerebrospinal fluid of HIV-1-infected patients.
PMID: 10428105
1999
Journal of acquired immune deficiency syndromes (1999)
Abstract: In 4, the lamivudine (3TC)-resistance mutation M184V was found in both CSF and plasma.
Abstract: In both, M184V was found in plasma but not CSF.
A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidine.
PMID: 10428942
1999
Antimicrobial agents and chemotherapy
Abstract: A similar increase in susceptibility to AZT and to PMPA was also conferred by the M184V mutation in RT.
Resistance profiles of (+)2'-deoxy-3'-oxa-4'-thiocytidine and (-)2'-deoxy-3'-oxa-4'-thio-5-fluorocytidine.
Abstract: Met184Val and Met184Ile, result in an increase in polymerase fidelity of the enzyme as measured in biochemical assays; however, the effect of such changes on the fidelity during viral replication is largely unknown.
Abstract: CONCLUSION: This study demonstrates that the Met184Val and Met184Ile mutations in the HIV-1 reverse transcriptase enzyme do not significantly affect the evolutionary potential of the corresponding viruses.
Abstract: DESIGN AND METHOD: In vitro selection experiments with either wild-type or lamivudine-resistant viruses (Met184Val and Met184Ile) were performed using a protease inhibitor as the selective drug.
Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity.
PMID: 10458616
1999
Journal of acquired immune deficiency syndromes (1999)
Abstract: An HIV strain encoding the M184V mutation was susceptible to the combination of MA and abacavir.
Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val.
Abstract: In replication kinetics assays, mutant Leu74Val replicated slower than the mutant Met184Val.
Abstract: The replication kinetics and RT processivity of the mutant with the Leu74Val mutation were compared to those of a lamivudine-selected mutant Met184Val.
Abstract: These observations provide biochemical evidence of decreased processivity to support the decrease in replication fitness observed with the Leu74Val or Met184Val mutations.
Abstract: The drug was most effective in patients with baseline isolates containing the M184V lamivudine resistance mutation according to data from a virological substudy of a large placebo-controlled trial.
Reduced antiretroviral drug susceptibility among patients with primary HIV infection.
Abstract: Population-based sequence analysis of these 3 samples identified multidrug-resistance mutations in reverse transcriptase (M184V, T215Y, K219K/R) and protease (L101/V, K20R, M361, M46I, G48V, L63P, A71T, V771, V82T, 184V, L90M) in the 2 latter patient samples, along with numerous polymorphisms.
HIV mutation literature information.
PMID: 
1999
AIDS (London, England)
Browser Board
Co-occurred Entities
Filtrator
ViMRT